Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients

NCT00493649 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT00493649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00493649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients
Lead sponsor
US Oncology Research
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
April 30, 2013
Enrollment
493 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer